BiondVax Pharmaceuticals Ltd. (BVXV) News
Filter BVXV News Items
BVXV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BVXV News From Around the Web
Below are the latest news stories about BIONDVAX PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate BVXV as an investment opportunity.
BiondVax Reports Second Quarter Financial Results and Provides Business UpdateJERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended J |
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesJERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previ |
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.LOS ANGELES, July 11, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel |
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisBroad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis.BiondVax to lead development and commercialization of NanoAbs with potential to neutralize IL-17A, IL-17F and IL-17A/F isoforms with high potency; ex vivo proof-of-concept expected this year, in vivo early next year.Psoriasis affects over 3% of U.S. population, with glo |
BVXV: Developing anti-IL-17 NanoAbBy David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Developing Anti-IL-17 NanoAb BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company that is focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. In March 2022, the company signed a |
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update(via IBN) -- BiondVax Pharmaceuticals Ltd.(Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the first quarter ended March 31, 2023, and provided a business update. |
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateJERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its full-year financial results for the year ended December 31, 2022, and provided a business update. At the same time, the Company filed its Annual Report on Form 10-K with the Securit |
BiondVax to Present at BIO-Europe SpringJERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring toge |
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir ReichmanLOS ANGELES, CA - (NewMediaWire) - March 06, 2023 - (InvestorBrandNetwork via NewMediaWire) - Multifaceted financial news and publishing company IBN today announces the release of the latest episode of the popular Test. The episode is hosted by Jason Fishman of Digital Niche Agency. |
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesLOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), recently appeared on the popular Test. Optimize. Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. The broadcast, hosted by Jason Fishman, SVP D |